Korean J Clin Oncol.  2019 Dec;15(2):61-67. 10.14216/kjco.19012.

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in management of peritoneal carcinomatosis: Single center experience in Korea

• Lee HJ
• Baik H
• Park YH
• Seo SH
• Kim KH
• Bae KB
• Hong KH
• Kim KH
• Byun JM
• Jeong DH
• Lee KB
• Oh MK
• Cho KR
• An MS

• KMID: 2470667
• DOI: http://doi.org/10.14216/kjco.19012

Abstract

PURPOSE
Peritoneal carcinomatosis (PC) has been considered a terminal condition and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIEPC) is regarded as an alternative therapeutic option. This study aimed to evaluate the 30-day clinical outcomes of CRS/HIPEC and the feasibility of the surgery by investigating the morbidity and mortality in Inje University Hospital.
METHODS
Data were retrospectively collected from 19 patients with PC who underwent CRS/HIPEC at Inje University Hospital in 2018. We evaluated pre-, intra-operative parameters and postoperative clinical outcomes and early complications.
RESULTS
The mean operating time was 506.95 minutes and the mean blood loss was 837.11 mL. Six cases (31.58%) had morbidity of grade III or above. A longer operating time (≥560 minutes, P=0.038) and large blood loss (≥700 mL, P=0.060) were positively correlated with grade III or worse postoperative complications.
CONCLUSION
Our early experience with CRS/HIPEC resulted in a 31.58% morbidity rate of grade III and above, with risk factors being longer operating time and greater intraoperative blood loss. As the surgical team's skills improve, a shorter operating time with less intraoperative blood loss could result in better short-term outcomes of CRS/HIPEC.

Keyword

Peritoneal carcinomatosis; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy

MeSH Terms

Carcinoma*
Drug Therapy*
Humans
Korea*
Mortality
Postoperative Complications
Retrospective Studies
Risk Factors